Anti-Glycan Antibody Innovation
Meeting the Unmet Need in Glycan Research
While hundreds of monoclonal antibodies (mAbs) have been developed against protein targets, the field of anti-glycan antibodies remains severely underdeveloped. Despite the critical role that carbohydrate structures play in cancer, infectious disease, and immune signaling, researchers face a shortage of well-characterized, specific, and reliable anti-glycan antibodies.
National Academy of Sciences has reported the lack of glycan-specific antibodies is a recognized barrier to advancing glycobiology. Existing reagents are few, often poorly characterized, and inconsistent across applications. This gap limits progress in both basic research and clinical translation.
Annular’s Approach
At AnnularBio, we believe this represents a unique opportunity for innovation.
Our combined technologies — proprietary Abitope Kits for hybridoma selection and collaborative glycan-display strategies — are designed to:
- Generate novel anti-glycan antibodies with higher affinity and selectivity
- Address linkage stereochemistry challenges, ensuring antibodies can distinguish glycan motifs with precision
- Provide panels of anti-glycan mAbs for diagnostics and therapeutic exploration
- Complement the growing databases of anti-glycan reagents (e.g., DAGR, GlycoEpitope) with new, validated entries
Why Glycans Matter:
- Cancer: Aberrant glycosylation patterns (e.g., Core2 O-glycans, sulfated glycans) drive tumor progression and immune evasion.
- Infectious Disease: Pathogen-specific glycans represent underutilized diagnostic and therapeutic targets.
- Immunology: Glycan recognition is central to immune cell activation and regulation.
By bridging this gap, AnnularBio aims to accelerate glycobiology research and provide the next generation of reagents that enable new discoveries and clinical applications.
